Cyclopropylamino Acid Amide as a Pharmacophoric Replacement for 2,3-Diaminopyridine. Application to the Design of Novel Bradykinin B1 Receptor Antagonists
Journal of Medicinal Chemistry2006Vol. 49(4), pp. 1231–1234
Citations Over TimeTop 11% of 2006 papers
Michael R. Wood, Kathy M. Schirripa, June J. Kim, Bang-Lin Wan, Kathy Murphy, Richard W. Ransom, Raymond S.L. Chang, Cuyue Tang, Thomayant Prueksaritanont, Theodore J. Detwiler, Lisa Hettrick, Elizabeth Landis, Yvonne Leonard, Julie A. Krueger, Sidney D. Lewis, Douglas J. Pettibone, Roger Freidinger, Mark G. Bock
Abstract
Antagonism of the bradykinin B1 receptor represents a potential treatment for chronic pain and inflammation. Novel antagonists were designed that display low-nanomolar affinity for the human bradykinin B1 receptor and good bioavailability in the rat.
Related Papers
- → Effects of bradykinin and bradykinin analogues on spleen cells of mice(1995)22 cited
- → Bradykinin receptors and signal transduction pathways in peritoneal guinea pig macrophages(1995)19 cited
- → Chapter 12. Bradykinin-1 receptor antagonists(2003)14 cited
- → Lipopolysaccharide decreases bradykinin receptor-induced acidification responses in cultured bovine aortic endothelial cells(2000)2 cited
- → The tachykinin NK1 receptor antagonist, RP67580, inhibits the bradykinin-induced rise in intracellular Ca2+ concentration in bovine pulmonary artery endothelial cells(1998)2 cited